Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer

Overview of attention for article published in Frontiers in immunology, February 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Readers on

mendeley: 10 Mendeley

Summary X Facebook

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 33,718 followers.

In base a questo studio, anche nelle persone molto anziane (75 anni o più) l'associazione immunoterapico-chemioterapia è decisamente superiore alla sola chemio... https://t.co/EhNUw3gB1s

14 Mar 2022

Reply Repost Favourite

New Research: Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer: Objective Several trials have shown that pembrolizumab plus… https://t.co/wqqSeFEF

14 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.